• Home
  • Products
  • Cagrilintide + Semaglutide Blend | 10mg-20mg | >99% Purity

Cagrilintide + Semaglutide Blend | 10mg-20mg | >99% Purity

(7)
169.99
189.99
Chemical Specifications (CagriSema Pre-Mixed Blend)
Product Name Cagrilintide + Semaglutide (Dual Satiety Matrix)
Total Net Yield 10mg to 20mg Options (1:1 Optimized Ratio)
Target Receptors GLP-1 Receptor (Semaglutide) + Amylin Receptor (Cagrilintide)
Component 1 (Semaglutide) CAS: 910463-68-2 | Formula: C187H291N45O59 | MW: 4113.6 g/mol
Component 2 (Cagrilintide) CAS: 1415456-99-3 | Formula: C181H285N45O56 | MW: 4047.5 g/mol
Purity (HPLC) ≥ 99.0% (Clinical/Research Grade for Both Compounds)
Appearance White Lyophilized Powder (Homogeneous Blend)
Primary Indication Severe Metabolic Plateaus / Extreme Satiety Control
Storage Store at 2°C to 8°C (Protect from light and moisture)
        SPECIAL OFFER

          Please select all product options

          Product was out of stock

          share
          Description
          🔥

          What is the Cagrilintide + Semaglutide Blend?

          Welcome to the ultimate metabolic override. This Pre-Mixed Dual Satiety Matrix (widely researched under the concept of CagriSema) combines the world’s most proven GLP-1 receptor agonist (Semaglutide) with the most advanced Long-Acting Amylin Analog (Cagrilintide) into a single, high-yield (10mg-20mg) lyophilized vial. Engineered for subjects who have developed a severe tolerance to standard GLP-1 monotherapy, this precision 1:1 blend eliminates the complex mathematics and contamination risks of manual stacking. It delivers an inescapable, two-pronged biological signal that completely silences food noise, forces extreme gastric delay, and shatters the most stubborn weight-loss plateaus known to modern science.

          Key Features & Dual-Synergy Mechanisms

          🧠

          Dual-Targeted Neuro-Satiety

          Semaglutide targets the hypothalamus, while Cagrilintide targets the hindbrain (area postrema). This creates a “Biological Checkmate” against hunger, shutting down the drive to eat from two completely independent neural pathways.

          🚀

          The Ultimate Plateau Breaker

          Designed specifically for subjects whose bodies have adapted to maximum doses of single GLP-1 therapies. Introducing the Amylin pathway forces the body to resume rapid fat oxidation without requiring higher GLP-1 dosages.

          ⚖️

          Precision Pre-Mixed Convenience

          Stop risking expensive peptides with manual “stacking” and complicated math. Our lab-grade pre-mix guarantees a perfect, homogeneous ratio in every single micro-dose, ensuring consistent and predictable research data.

          ⏳

          Extreme Gastric Emptying Delay

          The synergistic effect of GLP-1 and Amylin analogs slows digestive transit to an unprecedented degree. Subjects experience profound, long-lasting physical fullness from microscopic caloric intake, eliminating binge behaviors.

          🛡️

          Metabolic Adaptation Defense

          While severe diets usually crash the metabolism, early clinical models suggest the addition of an Amylin analog (Cagrilintide) helps maintain better lean mass ratios and insulin sensitivity during periods of extreme weight loss.

          🔬

          Massive 10mg-20mg Yield

          Available in ultra-high clinical volumes. This ensures researchers have more than enough active compound for extended, long-term titration protocols without needing to constantly reconstitute new, smaller vials.

          How It Works: The “Biological Checkmate” Against Hunger

          The biggest hurdle in extreme weight loss is biological adaptation. When a subject uses Semaglutide alone, the GLP-1 receptors in the brain eventually downregulate. The body gets “used to it,” the hunger slowly returns, the food noise creeps back in, and fat loss grinds to a devastating halt. The traditional solution was simply taking more GLP-1, which often leads to diminishing returns and harsh side effects.

          The Cagrilintide + Semaglutide Blend (CagriSema) solves this by opening a “Second Front.”

          Instead of hammering an exhausted GLP-1 receptor, this blend introduces Cagrilintide, a synthetic version of the hormone Amylin. Amylin operates on an entirely separate, untouched neurological pathway. While the Semaglutide continues to manage insulin and baseline satiety, the Cagrilintide hits the brainstem with a fresh, overwhelmingly powerful signal that the stomach is absolutely full.

          By simultaneously agonizing both the GLP-1 and Amylin receptors, you achieve a 1+1=10 effect. It is a synergistic explosion of satiety. The subject experiences an almost total eradication of appetite and cravings, paired with a drastically prolonged feeling of physical fullness. This dual-pathway override forces the body to break its metabolic stalemate, instantly re-initiating rapid, continuous adipose tissue breakdown.

          🧪 What’s In The Vial

          • Format: Pre-Mixed Lyophilized Powder
          • Component 1: Semaglutide (GLP-1 RA)
          • Component 2: Cagrilintide (Amylin Analog)
          • Total Net Yield: 10mg to 20mg Options
          • Purity: Clinical Grade (≥99%)

          👩‍🔬 Essential For

          • Breaking Severe Weight-Loss Plateaus
          • Subjects with GLP-1 Receptor Tolerance
          • Advanced Obesity & Metabolic Studies
          • Extreme Body Composition Remodeling

          🔗 Reconstitution Requirements

          • Solvent: Bacteriostatic Water (BAC)
          • Preparation: Gently swirl, do not violently shake
          • Storage: Store at 2°C to 8°C (Refrigerated)